Mostrar el registro sencillo del ítem
dc.contributor.author | White, Sara E. | |
dc.contributor.author | Harvey, Steven A. | |
dc.contributor.author | Meza, Graciela | |
dc.contributor.author | Llanos Cuentas, Elmer Alejandro | |
dc.contributor.author | Guzman Guzman, Mitchel Anthony | |
dc.contributor.author | Gamboa Vilela, Dionicia Baziliza | |
dc.contributor.author | Vinetz, Joseph Michael | |
dc.date.accessioned | 2018-11-30T02:09:28Z | |
dc.date.available | 2018-11-30T02:09:28Z | |
dc.date.issued | 2018 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/3987 | |
dc.description.abstract | BACKGROUND: A transmission-blocking vaccine (TBV) to prevent malaria-infected humans from infecting mosquitoes has been increasingly considered as a tool for malaria control and elimination. This study tested the hypothesis that a malaria TBV would be acceptable among residents of a malaria-hypoendemic region. METHODS: The study was carried out in six Spanish-speaking rural villages in the Department of Loreto in the Peruvian Amazon. These villages comprise a cohort of 430 households associated with the Peru-Brazil International Centre for Excellence in Malaria Research. Individuals from one-third (143) of enrolled households in an ongoing longitudinal, prospective cohort study in 6 communities in Loreto, Peru, were randomly selected to participate by answering a pre-validated questionnaire. RESULTS: All 143 participants expressed desire for a malaria vaccine in general; only 1 (0.7%) expressed unwillingness to receive a transmission-blocking malaria vaccine. Injection was considered most acceptable for adults (97.2%); for children drops in the mouth were preferred (96.8%). Acceptability waned marginally with the prospect of multiple injections (83.8%) and different projected efficacies at 70 and 50% (90.1 and 71.8%, respectively). Respondents demonstrated clear understanding that the vaccine was for community, rather than personal, protection against malaria infection. DISCUSSION: In this setting of the Peruvian Amazon, a transmission-blocking malaria vaccine was found to be almost universally acceptable. This study is the first to report that residents of a malaria-endemic region have been queried regarding a malaria vaccine strategy that policy-makers in the industrialized world often dismiss as altruistic. | en_US |
dc.language.iso | eng | |
dc.publisher | BioMed Central | |
dc.relation.ispartofseries | Malaria Journal | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | Peru | en_US |
dc.subject | Malaria | en_US |
dc.subject | Amazon | en_US |
dc.subject | Social acceptability | en_US |
dc.subject | Transmission-blocking vaccine (TBV) | en_US |
dc.title | Acceptability of a herd immunity-focused, transmission-blocking malaria vaccine in malaria-endemic communities in the Peruvian Amazon: an exploratory study | en_US |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | https://doi.org/10.1186/s12936-018-2328-z | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.03.07 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.03.08 | |
dc.relation.issn | 1475-2875 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |